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Abstract
Breast cancer is the leading cause of death among women and the contribution of circulating oestrogens to the growth of some mammary
tumours has been recognized. Consequently, suppression of oestrogen action by inhibition of their biosynthesis at the androstenedione-
oestrone aromatization step, by means of selective inhibitors of the enzyme aromatase, has become an effective therapeutic option for the
treatment of hormone-dependent breast cancer. Exemestane (6-methylenandrosta-1,4-diene-3,17-dione) is a novel steroidal irreversible
aromatase inhibitor recently approved and introduced into the global market under the name AromasinR. The design, laboratory and viable
syntheses of exemestane, starting from a variety of steroidal precursors, are presented and discussed. Data from biochemical and
pharmacological studies as well as the clinical impact of the compound are briefly reviewed. The drug is an orally active and well-tolerated
hormonal therapy for postmenopausal patients with advanced breast cancer that has become refractory to standard current hormonal
therapies. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Breast cancer is the leading cause of deaths among
women with 1 million new cases in the world each year
and with a rate of over 56 per 100,000 population in
Western Europe [1]. One-third of human breast tumours
are hormone-dependent [2] and epidemiological and exper-
imental evidence strongly supported that oestrogens are the
most important hormones involved in the growth of these
tumours [3]. The observation that administration or sub-
traction of hormones could interfere with the growth of
some tumours was first made over a century ago when
regression of metastatic breast carcinoma was achieved
successfully by ovariectomy [4], and significant advances
in the endocrine ablative therapy for breast cancer were
obtained with the introduction of bilateral adrenalectomy in
the fifties, and of hypophysectomy in the sixties, as a mean
of depleting oestrogens biosynthesis.
The development of hormone receptor measurements [5],
by allowing the identification of patients likely to respond to
hormonal therapy (60% of postmenopausal women), pro-
vided an impetus for the search and development of anti-
oestrogens, progestins, LH-RH antagonists and inhibitors of
oestrogen biosynthesis, in order to counteract oestrogen
action.
The agents used to block oestrogen biosynthesis as a
mean to deplete circulating oestrogen levels, highlighted the
importance of the enzyme aromatase as a rational target for
the effective and selective treatment for some postmeno-
pausal patients with hormone-dependent breast cancer [6,7].
Aromatase, a P-450-dependent enzyme, catalyses the
ultimate step in oestrogen biosynthesis (Scheme 1) that
converts androgens to oestrogens both in pre- and postme-
nopausal women [8]. While the main source of oestrogen
(primarily oestradiol) is the ovary in premenopausal women,
the principal source of circulating oestrogens in postmeno-
pausal women is from the aromatization of adrenal and
ovarian androgens (androstenedione and testosterone) to
oestrogens (oestrone and oestradiol) by the enzyme aroma-
tase in peripheral tissues (muscle, body fat).
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Testololactone, marketed under the name TESLACR,
and aminoglutethimide, marketed under the name
ORIMETENR, may be regarded as the pioneer drugs of
this type. The former has been used clinically in the treat-
ment of postmenopausal breast cancer for 20 years with
modest response rate, and later was discovered to be an
Scheme 1. Biosynthesis of oestrogens.
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irreversible aromatase inhibitor of very low potency [9]. The
latter, a nonsteroidal, nonspecific, reversible and compet-
itive inhibitor of aromatase, serendipitously showed its
endocrine properties after years of clinical use as an anti-
convulsant [10].
Since these drugs have been of some benefit in postme-
nopausal breast cancer but of moderate efficacy or tolerabil-
ity, the search and development of new, more potent, specific
and safer aromatase inhibitors became an attractive, shared
and well-founded option in the early 1980s. Efforts from
numerous research groups worldwide eventually produced a
selection of aromatase inhibitors, which are now in clinical
use or in advanced clinical trials [11–15] (Fig. 1), positioning
today these new agents in the mainstay of endocrine therapy
for breast cancer treatment [16–19,20a,b,21].
2. The enzyme aromatase and aromatase inhibitors
The aromatization of C19-steroids (androgens) to obtain
C18-steroids (oestrogens) is performed by the enzyme
complex aromatase (oestrogen synthetase). The complex
Fig. 1. Structure and classification of aromatase inhibitors in the clinical practice or in the clinical testing.
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consists of a flavoprotein, reduced nicotinamide adenine
dinucleotide phosphate (NADPH)–cytochrome P-450
reductase, that transfers electrons from NADPH to the
terminal enzyme, and a specific form of the cytochrome
P-450 enzyme system, known as aromatase cytochrome P-
450, which is the protein involved in the specific recog-
nition and binding of C19-steroid substrates. The protein
catalyzes a three-step oxidative reaction sequence at C-19
culminating in the cleavage of the angular C-19 methyl
group and in the aromatization of the ring A, releasing
formic acid and water (Scheme 2) [22]. The process is
allowed by the ability of the prosthetic group (haeme–iron
porphyrin complex) of aromatase to activate dioxygen for
insertion into C–H bonds. A number of postulated mech-
anisms have been considered over the years, and the ration-
alization of the third oxidative step as well as the
stereochemical outcome of the elimination of the 1- and
2-hydrogens are still matters for debate. It is not a purpose
of this paper to comment on various hypothesis, and authors
active in this field are only referred [23–32].
Since aromatase has both an iron-containing and a
steroid-binding site presenting two reasonable ways for
inhibition, aromatase inhibitors have been traditionally
divided into the two classes of Type I and Type II inhibitors.
2.1. Type II aromatase inhibitors
Type II aromatase inhibitors, such as aminoglutethimide,
rogletimide, fadrozole, anastrozole, letrozole and vorozole,
act by reversibly binding to the enzyme and by interfering
with the haeme–iron group of the cytochrome P-450 moiety
of the enzyme. A variety of enzymes possess cytochrome P-
Scheme 2. Conversion of androgens into oestrogens. A number of postulated mechanisms about the last oxidative step have been considered over the years.
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450 prosthetic groups, therefore, candidate inhibitors should
be carefully designed in order to be aromatase-specific.
Because they are reversible, ongoing oestrogen deprivation
depends upon the continued presence of the drug, thus
posing potential toxicity issues [13–15].
2.2. Type I aromatase inhibitors
Type I, or irreversible inhibitors (also known as suicide
or mechanism-based inactivators), such as testololactone,
formestane (4-hydroxyandrost-4-ene-3,17-dione (1)),
exemestane (6-methylenandrosta-1,4-diene-3,17-dione (2),
FCE 24304, PNU 155971), atamestane (1-methylandrosta-
1,4-diene-3,17-dione (3), SH 489) and plomestane (10h-(2-
propynyl)estr-4-ene-3,17-dione (4), MDL 18692) interact
with the substrate-binding site of the enzyme. They must
have an androstenedione-like structure and should be
designed in order to be transformed by the normal catalytic
action of the target enzyme into reactive species. Covalent
bond formation then occurs with a nucleophilic site of the
enzyme, leading to the irreversible inactivation of the target
enzyme by preventing enzyme catalysis from occurring
[11]. Because the inhibition is irreversible, renewed oestro-
gen production requires biosynthesis of new enzyme aro-
matase [15]. This would result in reduced side effects when
the inhibitor is used as a drug, since the inhibitor’s effect can
persist after its clearance from the system and the continuing
presence of the drug to maintain inhibition is thus not
necessary.
2.3. Formestane
As early as 1973, over 100 steroids were studied by the
group led by H. Brodie and A. Brodie for potential anti-
aromatase activity [33,34]. Candidate inhibitors were eval-
uated in vitro by comparing the extent of aromatization of
[1h,2h-3H]androstenedione to oestrogen in incubations of
microsomes from aromatase-containing tissues (human pla-
centa or ovaries of rats stimulated with pregnant mares’
serum gonadotropin, PMSG). The inhibitors with greatest
activity were 1,4,6-androstatriene-3,17-dione (6) [34,35], 4-
androstene-3,6,17-trione (7) [33] (Fig. 2), and 1 [36a]. All
showed Lineweaver–Burk plots typical of competitive
inhibition, which occurs rapidly in the presence of both
substrate (androstenedione) and inhibitor, and also caused
slower time-dependent loss of enzyme activity which fol-
lows pseudo first-order kinetics in microsomes preincubated
in the absence of substrate, but in presence of the cofactor
NADPH [36a]. No loss of activity occurred in the absence
of the cofactor. These findings suggested that all three
compounds caused long-term inactivation or irreversible
inhibition of aromatase, and that they can be regarded as
mechanism-based or suicide inhibitors.
The most interesting compound resulted to be 1, a po-
tential anabolizing agent previously synthesized in the
laboratories of Farmitalia [36b], which was evaluated clin-
ically in the 1980s under the name formestane [37] and
introduced into the market in 1993 under the name LEN-
TARONR (Ciba-Geigy, now Novartis) with the indication
for the treatment of advanced breast cancer in postmeno-
pausal women. In clinical trials, weekly deep intramuscular
injections with 500 mg of formestane to unselected breast
cancer patients resulted in a 60% suppression of plasma
oestradiol levels and an overall response rate of almost 30%.
Similar responses, obtained with a daily oral administration
of 500 mg, were however indicative of a poor bioavail-
ability by this route. A rapid metabolization of formestane
also occurs primarily as the glucoronide conjugate.
3. Exemestane
In order to overcome the unfavourable metabolism and
poor oral availability of 4-hydroxyandrostenedione, several
groups were engaged in the synthesis and pharmacological
evaluation of novel irreversible aromatase inhibitors with
improved oral activity. The group led by E. di Salle and P.
Lombardi at Farmitalia Carlo Erba (now Pharmacia)
designed, synthesised and evaluated the novel steroid 2
(FCE 24304, exemestane). Despite impressive steroid
chemistry conducted over the previous decades, the struc-
ture of exemestane resulted a new one. The design of the
Fig. 2. Androstenedione-like structures tested as aromatase inhibitors.
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molecule was derived by early findings that effective
aromatase inhibitors resemble the androst-4-ene-3,17-dione
substrate sterically and electronically, and that better inhib-
ition was found in derivatives containing the D4-3,6-dione,
D1,4,6-3-one or the D4,6-3-one moieties [33]. The 6-keto and
D6 groupings of these compounds extend linear conjugation
of the parent D4-3-one system and the enzyme system
appeared to bind well to these longer, delocalised k bond
systems. Exemestane was found to inhibit human placental
aromatase with a potency similar to formestane (in com-
parative experiments, IC50 = 42 and 44 nM, respectively)
and in preincubation studies exemestane caused time-
dependent (irreversible) inactivation of the enzyme [38,39].
However, both androsta-4,6-diene-3,17-dione (8) [24]
and 6-methylenandrost-4-ene-3,17-dione (9) [38] are not
time-dependent inactivators, and irreversible aromatase
inhibition exibited by exemestane as well as by 6, and
1,4-androstadiene-3,17-dione (10), may rely on the lack of
the 1h-hydrogen. At the time these compounds were under
characterization, a postulated mechanism for conversion of
androgens into oestrogens hypothesised the formation of an
enzyme-bound intermediate 5 [24]. This intermediate col-
lapses to an aromatized product via elimination of the 1h-
hydrogen and enolisation of the resulting keto-diene moiety,
which releases the oestrogen and simultaneously regenerates
the unaltered and active free enzyme (Scheme 2). In the
presence of the 1,2-double bond, the enzyme-bound inter-
mediate will aromatize without undergoing the final elimi-
nation reaction. Thus, the 1,2-unsaturation acts as a latent
alkylating group (Scheme 3).
Exemestane entered preclinical development in 1986,
and successfully performed clinical trials during the 1990s
to receive FDA approval on October 21, 1999 for the treat-
ment of advanced breast cancer in postmenopausal women
whose disease has progressed following tamoxifen (antioes-
trogen) therapy. The compound, marketed under the name
AROMASINR (Pharmacia), is the first oral aromatase in-
activator.
3.1. Chemistry
The direct introduction of a methylene group at 6-po-
sition of a 3-oxo-4-ene steroid is a known process. There-
fore, the laboratory synthesis of exemestane, 2, (Scheme 4)
[40] exploited the 6-methylenation of androstenedione with
formaldehyde acetal and POCl3 to give 9, according to the
general method of Annen et al. [41]. The introduction of
the required 1,2-double bond to obtain 2 was then per-
Scheme 3. Postulated aromatase inactivation mechanism by 1,4-androsta-
diene-like structures.
Scheme 4. Laboratory synthesis of exemestane (2).
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formed by dichlorodicyanobenzoquinone (DDQ) dehydro-
genation.
In order to overcome the disadvantages and drawbacks of
these methods, represented by low yields, high price of
DDQ and chromatographic purifications, other processes
amenable to be scaled up were developed at Farmitalia
Carlo Erba.
A more original and practical synthetic approach, start-
ing from commercially available dehydrotestosterone, dis-
closed an unusual and unprecedented Mannich reaction on a
cross-conjugated dienone moiety by fetching the direct
introduction of the methylene group at the 6-position of a
3-oxo-1,4-diene steroid, performed with paraformaldehyde
and dimethylamine in iso-amylic alcohol (i-AmOH) at 130
jC (Scheme 5) [42]. The hydroxyl function at C-17 of the
ring D of the starting steroid must be initially present to
avoid a competitive Mannich reaction occurring preferen-
tially at C-16 if the 17-oxo analogue would have been the
synthetic precursor. The 6-methylene intermediate (11),
obtained by precipitation from the above reaction mixture
in 35% yield, gave exemestane, 2, in 28% overall yield,
after crystallisation of the solid residue resulting from the
work-up of the Jones oxidation to introduce the 17-keto
group.
An alternative synthetic viable route of exemestane was
also set up after having performed a remarkably efficient 6-
methylenation of the less expensive and more readily
available androstenedione with a corporate know-how used
in the industrial synthesis of Farmitalia’s medroxyproges-
terone acetate (Scheme 6) [43,44]. Accordingly, androste-
nedione was first reacted with triethylorthoformate in
tetrahydrofuran (THF)–EtOH at 40 jC in the presence of
para-toluenesulfonic acid ( p-TsOH). The resulting ethyl
3,5-dienolether without isolation was subjected to Mannich
reaction with N-methylaniline and aqueous formaldehyde.
The adduct intermediate was decomposed with concentrated
HCl and the resulting 6-methylene intermediate 9 was
obtained in 73% yield after simple precipitation. The intro-
duction of the double bond at 1,2-position of the 3-oxo
steroid skeleton can be also easily carried out by bromina-
tion–dehyrobromination. However, in the present case,
bromination of 9 with bromine in THF–AcOH at 0 jC
and a catalytic amount of HBr afforded the expected
tribromide (12) in 84% yield and in almost pure form after
precipitation. Partial debromination with sodium iodide in
refluxing acetone provided the crude 2-bromointermediate,
which was dehydrohalogenated with LiCl and LiCO3 in
N,N-dimethylformamide (DMF) at 120 jC to give exemes-
tane, 2, by precipitation with water in 47% yield based on
androstenedione.
A recent Pharmacia process entailed the enzymatic 1,2-
dehydrogenation of 9 (Scheme 7) [45]. Accordingly, the
intermediate 9 and whole cells of Arthrobacter simplex were
mixed and agitated during some days in toluene and water
in the presence of menadione, as a radical scavenger, and
phosphate buffer. Exemestane, 2, was collected from the
toluene phase after concentration and precipitation with
octane.
3.2. Biology
The properties of exemestane were compared in vitro and
in vivo with the structurally related compounds 9 and 10
[38]. In initial co-incubation studies with the substrate, all
three steroids were found to inhibit human placental aro-
matase, being exemestane the more potent (Table 1). How-
ever, this experiment gives only a preliminary indication of
the compounds’ inhibitory potency, since the values could
be the result of both competitive and time-dependentScheme 5. Viable synthesis of exemestane (2) from dehydrotestosterone.
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enzyme inhibition. In pre-incubation studies (0–32 min
with human placental aromatase and in the presence of
NADPH) both exemestane, 2, and 10 induced time-depend-
ent enzyme inactivation, whereas no time-related decrease
in aromatase activity was observed with the 6-methylene
derivative 9 (Table 2). Exemestane showed a higher aroma-
tase affinity than 10 (Ki = 26 and 92 nM, respectively) and a
faster enzyme inactivation (t1/2 = 13.9 and 24.1 min, respec-
tively).
For in vivo studies, female rats with PMSG-stimulated
ovarian aromatase were used. Twenty-four hours after dos-
ing (10 mg/kg subcutaneously), 9 was completely inactive,
10 lowered ovarian aromatase to 66% of the control value,
whereas inhibition was far more pronounced with exemes-
tane which reduced ovarian aromatase to 19% of control
activity (Table 3). In further dose–response studies, exem-
estane was shown to reduce ovarian aromatase with an ED50
of 1.8 mg/kg (s.c.) and, much interestingly, the compound
was also very potent when given orally, its ED50 being 3.7
mg/kg (p.o.) (Fig. 3).
The antitumour activity of exemestane was studied in rats
with 7,12-dimethylbenzanthracene (DMBA)-induced
tumours. Exemestane given s.c. induced 44% tumour
regression at a dose of 3 mg/kg per day and, when the
compound was given orally on the same treatment schedule,
tumour regressions amounted to 50% at 100 mg/kg [46].
However, in the DMBA-induced mammary tumour in
ovariectomized female rats treated with testosterone, a
postmenopausal breast cancer model, exemestane was
shown to be highly effective by both s.c. (88% and 96%
tumour regression at 10 and 50 mg/kg daily, respectively),
and oral routes (76% and 88% tumour regression at the
same doses) [47].
The properties of exemestane were also compared with
those of steroidal aromatase inhibitors developed by other
research groups, namely formestane, 1, atamestane, 3, and
plomestane, 4 [39]. In initial coincubation studies with the
substrate, atamestane was found to be the most potent
inhibitor, showing an IC50 of 20.3 nM, compared to 31.3
nM for plomestane, 42.5 nM for exemestane, and 43.7 nM
Scheme 6. Viable synthesis of exemestane (2) from androstenedione.
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for formestane. In preincubation studies with the enzyme,
formestane, atamestane and plomestane caused, like
exemestane, time-dependent enzyme inhibition, and striking
differences between them were observed. Formestane was
the fastest aromatase inactivator, showing a tl/2 of 2.1 min,
whereas plomestane had a t1/2 of 13.1 min, similar to
exemesatne (13.9 min), and atamesatne was the slowest
inactivator, with a tl/2 of 45.3 min. Plomestane and atames-
tane showed very high affinity for the enzyme, having a Ki
of 0.7 and 2.0 nM, respectively, compared to 26.0 nM for
exemestane and 29.0 nM for formestane.
However, the most striking and significant differences
were observed in vivo in the PMSG-pretreated rat experi-
ment. Compared to formestane, plomestane and atamestane,
exemestane was the most potent compound after both
subcutaneous and oral admnistration, giving ED50 values
of 1.8 and 3.7 mg/kg, respectively. Plomestane showed the
same potency as exemestane only by the subcutaneous route
(ED50 1.4 mg/kg) and was less effective orally (ED50 18
mg/kg). Formestane caused enzyme inactivation after sub-
cutaneous dosing (ED50 3.1 mg/kg), but had scant effect
even at 100 mg/kg orally. Atamestane, despite its very high
enzyme affinity, caused very low enzyme inactivation even
subcutaneously (Table 4). In comparative DMBA-induced
mammary tumour studies in rats, the antitumour efficacy of
exemestane was much greater than that of atamestane,
plomestane and formestane [48,49].
3.3. Clinical efficacy
In healthy postmenopausal volunteers, which were given
single oral doses of exemestane ranging from 0.5 to 800 mg,
the minimal effective dose in decreasing oestrogen levels
was 5 mg and the minimal dose which produced the
maximum suppression of plasma oestrogens, observed at
day 3 and persisting on day 5, was 25 mg. The long-lasting
inhibitory effect of exemestane on oestrogen synthesis is
likely due to the irreversible nature of its enzyme inhibitory
property, rather than to its pharmacokinetic properties. In
fact, the drug was rapidly adsorbed and reached peak levels
within 2 h after oral administration, rapidly disappearing
thereafter [50, 51].
Exemestane was extensively metabolized in all species.
The initial steps are the reduction of the 17-keto group to
give the 17h-hydroxy steroid 11, and the oxidation of the
methylene group in position 6 with subsequent formation of
many secondary metabolites, identified by comparison with
synthetic reference compounds (Fig. 4) [52,53]. All metab-
olites were found to be either inactive in inhibiting aroma-
tase or less potent than exemestane, thus excluding a
possible contribution of any metabolite to the observed
prolonged effect of the drug.
In earlier clinical studies with heavily pretreated, post-
menopausal patients with advanced breast cancer failing
multiple hormonal treatments, exemestane, at repeated daily
oral doses ranging from 5 to 600 mg, caused a maximal
Scheme 7. Microbiological conversion of 6-methylenandrostenedione (9) to
exemestane (2).
Table 1
In vitro inhibition of human placental aromatase
Compound IC50 (nM)
Exemestane (2) 42.5
6-Methylenandrostenedione (9) 110.5
1,4-Androstadienedione (10) 81.1
The compounds were co-incubated for 15 min with substrate
[1h,2h-3H]androstenedione (50 nM).
Table 2
Time-dependent aromatase inhibition
Compound Ki (nM) t1/2 (min)
Exemestane (2) 26 13.9
6-Methylenandrostenedione (9) no time-dependent inhibition observed
1,4-Androstadienedione (10) 92 24.1
The compounds were pre-incubated for 0–32 min with human placental
aromatase in the presence of NADPH.
Table 3
Effect of subcutaneous dosing on ovarian aromatase activity in PMSG-
stimulated rats
Compound Dose
(mg/kg, s.c.)
Ovarian aromatase
(% controls)
Vehicle – 100
Exemestane (2) 10 19
6-Methylenandrostenedione (9) 10 104
1,4-Androstadienedione (10) 10 66
Aromatase activity remaining was determined in the ovarian microsomal
fraction obtained 24 h after inhibitor dosing.
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inhibition (>90%) of plasma oestrogens starting from the
lower doses. An objective positive response was observed in
up to 33% of evaluable patients, which was promising
considering that exemestane was administered as third- or
fourth-line hormonal treatment in most cases [54–57].
The minimal effective exemestane oral dose for endo-
crine activity in advanced breast cancer patients was
assessed at 0.5 mg/day, achieving oestrogen suppression
of about 25–30% versus baseline starting from day 7 of
treatment [58]. The most favourable effects, as maximal
suppression of oestrogens, tolerability and antitumour activ-
ity, were observed at 25 mg daily oral dose and a large, safe
therapeutic window of up to 600 mg was defined [59,60].
A study aimed at determining the effect of exemestane on
in vivo aromatization in postmenopausal women with
advanced breast cancer showed, that at 25 mg daily oral
dose exemestane inactivated peripheral aromatase activity
by approximately 98% and reduced basal plasma oestrone,
oestradiol and oestrone sulfate levels by 85% to 95% after
6–8 weeks of therapy, with respect to values before treat-
ment [61].
In later clinical trials, exemestane improved survival time
in postmenopausal patients with either advanced breast
cancer or metastatic breast cancer, who had previously
failed on the antioestrogen agent tamoxifen or on non-
steroidal aromatase inhibitors treatment [62–66]. Ongoing
clinical studies, aimed at comparing exemestane with
tamoxifen as first-line therapy in metastatic breast cancer,
already showed a preliminary, higher anti-tumour efficacy
of 42–44% positive responses for exemestane versus 14–
16% for tamoxifen [67,68].
4. Conclusions
Over the past decade, novel aromatase inhibitors have
been discovered and introduced into the clinical practice, on
the observation that the main mechanism of action of
Fig. 3. Effect of subcutaneous and oral dosing of exemestane (2) on ovarian
aromatase activity in PMSG-stimulated rats. Aromatase activity remaining
was determined in the ovarian microsomal fraction obtained 24 h after
inhibitor dosing and expressed as percentage (%) of controls.
Fig. 4. Metabolites of exemestane (2). Exemestane is extensively
metabolized to the 17h-hydroxy derivative (11) and to other compounds
following oxidation of the 6-exomethylene group (X =OH, Y=H;
X,Y=O).
Table 4
Effect of oral dosing on ovarian aromatase activity in PMSG-stimulated rats
Compound Dose
(mg/kg, orally)
Ovarian aromatase
(% controls)
ED50
(mg/kg, orally)
Exemestane (2) 1 67.8 3.7
3 53.6
10 34.8
30 23.6
Formestane (1) 10 79.9 > 100
30 75.7
100 71.6
Plomestane (4) 3 71.6 18
10 57.4
30 43.7
Atamestane (3) 30 76.8 >100
100 89.2
Aromatase activity remaining was determined in the ovarian microsomal
fraction obtained 24 h after inhibitor dosing.
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aminoglutethimide was via inhibition of the enzyme aroma-
tase, thereby reducing levels of circulating oestrogens in
postmenopausal breast cancer patients.
The second generation drug was 1 (formestane),
introduced into the market in 1993 under the name
LENTARONR. Although its use was limited by its need
to be given parenterally, it was found to be a well-tolerated
form of endocrine therapy.
Third-generation inhibitors include anastrozole, letrozole,
vorozole and exemestane, the former three being nonsteroidal
competitive inhibitors, the latter being a steroidal irreversible
inhibitor. All are capable of inhibiting aromatase action by
>90% compared to 80% in the case of formestane.
Exemestane (AROMASINR), a rationally designed,
selective, orally active, long-lasting and safe hormonal drug,
has demonstrated impressive pharmacologic and clinical
properties in improving the treatment of breast cancer pa-
tients. It has also showed a great potential to be more effective
as first-line treatment than other current drugs, comprising
antioestrogens and nonsteroidal aromatase inhibitors.
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